United States
Founded in 2003, the company has carved a niche for itself in the preclinical and phase 1 through phase 3 oncology trials in North America and Europe. Medelis sets itself apart by offering sponsors access to a wealth of oncology expertise, from thought leadership in drug development to a highly skilled clinical operations team capable of overseeing complex oncology trials in all indications, including cutting-edge immunotherapy treatments. The company's commitment to oncology is reflected in its focus on Biotechnology, Pharmaceutical, and Clean Energy industries, underscoring its dedication to driving innovation in these sectors.
Headquartered in the United States, Medelis, Inc. remains a key player in the fight against cancer, attracting attention from potential investors seeking to support groundbreaking oncology research and development. Although information on its last investment and the involved investors is currently unavailable, Medelis, Inc. draws attention for its potential as an impactful and pioneering force within the field of oncology, making it an intriguing prospect for venture capital firms.
